Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2009-08-19 Director's Dealing
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
STEWART FORM 4
Director's Dealing
2009-08-19 English
L. RAHN STOCK OPTION GRANT 03/2009
Director's Dealing
2009-08-19 English
C. MCKENNEY STOCK OPTION GRANT 03/2009
Director's Dealing
2009-08-19 English
E. FRYKMAN STOCK OPTION GRANT 03/2009
Director's Dealing
2009-08-19 English
REVISED PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Revised Preliminary Proxy Statement filed under Schedule 14A with the SEC, which is used to solicit shareholder votes on specific proposals for a special meeting. It includes detailed information about the meeting date, proposals to be voted on (such as reverse stock split, increasing authorized shares, and equity grants), voting instructions, and other procedural details. This type of document is specifically designed to provide information to shareholders to enable informed voting decisions at a shareholder meeting. It is not an annual report, earnings release, or other financial report, but rather a proxy solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or a brief notice.
2009-08-19 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Preliminary Proxy Statement' and is filed as a Schedule 14A with the SEC, which is a standard form for proxy solicitation materials. It includes detailed information about a Special Meeting of Stockholders, including proposals to be voted on, voting procedures, record dates, and interests of certain persons. The content focuses on soliciting votes for corporate actions such as a reverse stock split, amendment of the certificate of incorporation, and equity grants. It does not contain financial statements or earnings data, nor is it a report of voting results or a notice of dividend. The document is a proxy solicitation material intended to inform shareholders and request their votes, which fits the definition of a Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the statement itself, not just an announcement of its availability.
2009-08-18 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.